US Bancorp vs Zimmer Biomet Holdings Inc — how do they compare? US Bancorp trades at $64.81 (market cap $100.17B), while Zimmer Biomet Holdings Inc trades at $95.94 (market cap $18.55B). The key difference: US Bancorp is far larger — about 5.4× Zimmer Biomet Holdings Inc's market cap, and US Bancorp pays the higher dividend (3.24%). Which is the better fit depends on your goals.
| USB | ZBH | |
|---|---|---|
Market Cap | $100.17B | $18.55B |
Sector | Financials | Health |
52-Week High | $64.47 | $107.71 |
52-Week Low | $45.28 | $79.58 |
Dividend Yield | 3.24% | 0.99% |
Enterprise Value | — | $25.61B |
Signals from Pluang's Aura AI — not financial advice
U.S. Bancorp (USB) trades at $64.19, up 0.39% today, with a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $1.35 surpassing the $1.28 expectation. Revenue and net income have shown steady growth, with 2025 revenue at $28.54 billion and net income at $7.57 billion. Analyst sentiment is positive, with a consensus price target of $70.27, indicating potential upside.
The outlook for USB is favorable, supported by robust earnings growth, a solid dividend, and positive analyst ratings. Key risks include exposure to interest rate fluctuations and macroeconomic volatility, as highlighted by recent news on potential Fed rate hikes. Institutional investors have been increasing stakes, reinforcing confidence. The stock presents a compelling opportunity for value-oriented investors seeking steady returns amid a stable banking sector.
ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.
The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.
Trailing returns across standard periods
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →